脯氨酸羟化酶抑制剂治疗肾性贫血和缺血性心脏病的研究进展

Research progress of hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of renal anemia and ischemic heart disease

低氧诱导因子是在缺氧或低氧时启动适应性转录反应的主要调节因子,其在常氧环境下被脯氨酸羟化酶羟基化后降解失去活性。脯氨酸羟化酶抑制剂是一种新上市的小分子口服制剂,通过抑制脯氨酸羟化酶,减少低氧诱导因子的降解,从而激活低氧诱导途径,调节包括刺激红细胞生成、铁吸收和动员、血管生成、脂质和糖代谢、炎症、能量代谢、细胞生长和分化等多种生理反应,展现出较多临床益处。近年来,脯氨酸羟化酶抑制剂在肾性贫血领域的应用已经取得了明确的疗效,并且在缺血性心脏病领域中的研究也取得了较大的进展,未来在缺血性心脏病治疗等方面有良好的应用前景。

The hypoxia-inducible factor is a significant regulator of adaptive transcriptional response in hypoxia or hypoxia.Hypoxia-inducible factor(hypoXIA-inducible factor)loses its activity after hydroxylation by proline hydroxylase in a normoxic environment.Proline hydroxylase inhibitor is a kind of new small molecule oral preparation by inhibiting the proline hydroxylase,reducing the degradation of HIF,activating the hypoxia-induced way,adjusting including stimulates erythropoiesis,iron absorption and mobilization,angiogenesis,lipid,and glucose metabolism,inflammation,energy metabolism,cell growth and differentiation,and other physiological reaction,Showed more clinical benefits.In recent years,the application of proline hydroxylase inhibitors in the field of renal anemia has achieved apparent efficacy,and the research in the field of ischemic heart disease has also made significant progress in the future in the treatment of ischemic heart disease and other aspects of good application prospects.